PubRank

R M Bertina

Author PubWeight™ 240.73‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996 6.05
2 Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1994 5.58
3 Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994 5.45
4 Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2006 3.03
5 High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000 2.39
6 Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles. J Thromb Haemost 2009 2.33
7 Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998 2.26
8 Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999 2.04
9 Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 1983 2.03
10 Inherited thrombophilia: Part 1. Thromb Haemost 1996 2.00
11 The putative factor IX gene promoter in hemophilia B Leyden. Blood 1988 1.98
12 Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993 1.96
13 von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 2006 1.84
14 High levels of factor IX increase the risk of venous thrombosis. Blood 2000 1.61
15 Nucleotide sequence of a cDNA for a member of the human 90-kDa heat-shock protein family. Gene 1987 1.60
16 Cerebral haemorrhagic infarction in young patients with hereditary protein C deficiency: evidence for "spontaneous" cerebral venous thrombosis. Br Med J (Clin Res Ed) 1985 1.58
17 Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost 2007 1.55
18 Hereditary protein S deficiency: clinical manifestations. Ann Intern Med 1987 1.53
19 Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin therapy. Clin Chem 1997 1.46
20 Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000 1.45
21 Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Br J Haematol 1996 1.39
22 Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemost 1982 1.37
23 Inherited thrombophilia: Part 2. Thromb Haemost 1996 1.34
24 Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J Thromb Haemost 2004 1.33
25 Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001 1.33
26 Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985 1.33
27 Procoagulant activity of endocardial vegetations and blood monocytes in rabbits with Streptococcus sanguis endocarditis. Thromb Haemost 1989 1.31
28 Determination of plasma protein S--the protein cofactor of activated protein C. Thromb Haemost 1985 1.31
29 Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012 1.29
30 Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden. Proc Natl Acad Sci U S A 1992 1.29
31 Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995 1.28
32 Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994 1.27
33 Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 2009 1.19
34 The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents. Thromb Haemost 1989 1.19
35 Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. Arterioscler Thromb Vasc Biol 1997 1.17
36 Stimulation of monocyte tissue factor expression in an in vitro model of bacterial endocarditis. Infect Immun 1994 1.17
37 The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J 1990 1.17
38 The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemost 1984 1.17
39 Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost 1999 1.17
40 Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty. N Engl J Med 1982 1.16
41 Two genes homologous with human protein S cDNA are located on chromosome 3. Thromb Haemost 1987 1.14
42 Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005 1.14
43 An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). Blood 1997 1.14
44 Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost 1983 1.13
45 Protein C deficiency in two Austrian families. Thromb Haemost 1983 1.12
46 Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain. Eur J Biochem 1987 1.10
47 Two novel point mutations correlate with an altered developmental expression of blood coagulation factor IX (hemophilia B Leyden phenotype). Blood 1989 1.09
48 ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost 2005 1.08
49 Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. Arterioscler Thromb Vasc Biol 1995 1.08
50 Considerations on the true value of the international normalized ratio in the control of oral anticoagulant therapy. Br J Haematol 1994 1.07
51 Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance. Thromb Haemost 1997 1.07
52 The binding of aurovertin to mitochondria, and its effect on mitochondrial respiration. Biochim Biophys Acta 1973 1.06
53 Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch families. Thromb Haemost 1985 1.06
54 Intron-exon organization of the active human protein S gene PS alpha and its pseudogene PS beta: duplication and silencing during primate evolution. Biochemistry 1990 1.05
55 Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995 1.05
56 Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke 1995 1.04
57 Congenital protein C deficiency and thrombotic disease in nine French families. Br Med J (Clin Res Ed) 1984 1.04
58 Hemophilia B Leyden: substitution of thymine for guanine at position -21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoter. Blood 1993 1.03
59 Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost 1999 1.02
60 A Dutch family with moderately severe hemophilia B (factor IXHeerde) has a missense mutation identical to that of factor IX London 2. Nucleic Acids Res 1989 1.02
61 The role of factor VIII in the activation of human blood coagulation factor X by activated factor IX. Thromb Haemost 1985 1.01
62 Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost 2001 1.01
63 G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3'-end formation. J Thromb Haemost 2004 1.00
64 Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions. Thromb Haemost 1987 0.99
65 Influence of monocytes and antibiotic treatment on tissue factor activity of endocardial vegetations in rabbits infected with Streptococcus sanguis. Infect Immun 1996 0.99
66 Combined hereditary deficiency of the sixth component of complement and factor VIII coagulant activity in a Dutch family. Clin Exp Immunol 1982 0.99
67 Pathways in the activation of human coagulation factor X. Biochem J 1980 0.97
68 Localization of factor VIII-procoagulant antigen: an immunohistological survey of the human body using monoclonal antibodies. Blood 1986 0.97
69 Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol 1999 0.96
70 Five novel intragenic dimorphisms in the human interleukin-1 genes combine to high informativity. Cytokine 1996 0.96
71 Binding of human blood-coagulation Factors IXa and X to phospholipid membranes. Biochem J 1984 0.96
72 A Dutch pedigree with mild hemophilia B with a missense mutation in the first EGF domain (factor IXOud en Nieuw Gastel). Nucleic Acids Res 1989 0.95
73 Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 1996 0.95
74 Plasma fibrinogen gamma' chain content in the thrombotic microangiopathy syndrome. J Thromb Haemost 2006 0.93
75 The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. Blood 1991 0.93
76 Role of monocytes in experimental Staphylococcus aureus endocarditis. Infect Immun 2000 0.93
77 Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb Haemost 2001 0.92
78 Inhibition of thrombin-mediated factor V activation contributes to the anticoagulant activity of fibrinogen γ'. J Thromb Haemost 2013 0.92
79 Factor IX Deventer-evidence for the heterogeneity of hemophilia BM. Thromb Haemost 1982 0.92
80 A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999 0.92
81 Two mutations of the factor IX gene including a donor splice consensus deletion and a point mutation in a Dutch patient with severe hemophilia B. Thromb Haemost 1990 0.92
82 Functional characterization of transcription factor binding sites for HNF1-alpha, HNF3-beta (FOXA2), HNF4-alpha, Sp1 and Sp3 in the human prothrombin gene enhancer. J Thromb Haemost 2003 0.92
83 Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen gamma'/gammaA mRNA ratio. J Thromb Haemost 2007 0.92
84 Protein S deficiency associated with "juvenile" arterial and venous thromboses. Thromb Haemost 1986 0.91
85 The mechanism of inhibition by oligomycin of oxidative phosphorylation in mitochondria. Biochim Biophys Acta 1974 0.90
86 Hereditary protein C-deficiency: laboratory values in transmitters and guidelines for the diagnostic procedure. Report on a study of the SSC Subcommittee on Protein C and Protein S. Protein C Transmitter Study Group. Thromb Haemost 1992 0.89
87 The 46C-->T polymorphism in the factor XII gene (F12) and the risk of venous thrombosis. J Thromb Haemost 2005 0.89
88 Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001 0.89
89 Inter-relation of coagulation factors and d-dimer levels in healthy individuals. J Thromb Haemost 2003 0.89
90 Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin. Thromb Haemost 1998 0.89
91 The contribution of Ca2+ and phospholipids to the activation of human blood-coagulation Factor X by activated Factor IX. Biochem J 1984 0.89
92 Functional analysis of two prothrombin 3'-untranslated region variants: the C20209T variant, mainly found among African-Americans, and the C20209A variant. J Thromb Haemost 2006 0.89
93 Mesenteric vein thrombosis as presenting manifestation of hereditary protein S deficiency. Gastroenterology 1987 0.88
94 Extrinsic activation of human coagulation factors IX and X on the endothelial surface. Thromb Haemost 1991 0.88
95 A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 1998 0.88
96 Hereditary protein S deficiency. Haemostasis 1985 0.88
97 Lipopolysaccharide induction of tissue factor in THP-1 cells involves Jun protein phosphorylation and nuclear factor kappaB nuclear translocation. J Biol Chem 1999 0.88
98 The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. Thromb Haemost 1996 0.87
99 The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thromb Haemost 1987 0.87
100 Interleukin 10-2849AA genotype protects against pre-eclampsia. Genes Immun 2004 0.87
101 Venous thrombosis--the interaction of genes and environment. N Engl J Med 1998 0.87
102 Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost 1998 0.87
103 The inhibitor of prothrombin conversion in plasma of patients on oral anticoagulant treatment. Thromb Haemost 1981 0.87
104 Role of monocytes and bacteria in Staphylococcus epidermidis endocarditis. Infect Immun 1998 0.86
105 Beta 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992 0.86
106 Detection of carriers of haemophilia B. Br J Haematol 1979 0.86
107 Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995 0.86
108 Human protein S cDNA encodes Phe-16 and Tyr 222 in consensus sequences for the post-translational processing. FEBS Lett 1987 0.86
109 Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder. Thromb Haemost 1994 0.86
110 A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001 0.86
111 High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 2001 0.85
112 Interaction of thromboplastin apoprotein of different tissues with concanavalin A--evidence for heterogeneous glycosylation of the human apoprotein. Thromb Haemost 1984 0.85
113 Homozygous protein S deficiency due to a one base pair deletion that leads to a stop codon in exon III of the protein S gene. Thromb Haemost 1994 0.85
114 A frequent thrombomodulin amino acid dimorphism is not associated with thrombophilia. Thromb Haemost 1991 0.85
115 Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulin-like domain. Biochem J 1998 0.85
116 Scatchard plot and heterogeneity in binding affinity of labeled and unlabeled ligand. Clin Chem 1975 0.85
117 Type I protein C deficiency caused by disruption of a hepatocyte nuclear factor (HNF)-6/HNF-1 binding site in the human protein C gene promoter. J Biol Chem 1998 0.85
118 Familial thrombophilia: a complex genetic disorder. Semin Hematol 1997 0.85
119 Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease. Br J Haematol 2006 0.85
120 Factor V Leiden and fatal pulmonary embolism. Thromb Haemost 1998 0.85
121 Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994 0.84
122 Plasma levels of microparticle-associated tissue factor activity in patients with clinically suspected pulmonary embolism. Thromb Res 2010 0.84
123 Matrix metalloproteinase-9 gene -1562C/T polymorphism mitigates preeclampsia. Placenta 2006 0.84
124 The abnormal factor IX of hemophilia B+ variants. Thromb Haemost 1978 0.84
125 Screening for the FV:Q506 mutation--evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost 1997 0.84
126 Sequence variants and haplotypes of the factor IX gene and the risk of venous thrombosis. J Thromb Haemost 2008 0.84
127 Coagulation factors in the human fetus of about 20 weeks of gestational age. Br J Haematol 1980 0.84
128 Activation of human coagulation factor VIII by activated factor X, the common product of the intrinsic and the extrinsic pathway of blood coagulation. Thromb Haemost 1982 0.84
129 Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci. J Thromb Haemost 2003 0.84
130 Partial protein S gene deletion in a family with hereditary thrombophilia. Blood 1989 0.84
131 Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. Br J Haematol 2000 0.83
132 Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost 2004 0.83
133 Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost 2005 0.83
134 Tissue factor expression during monocyte-macrophage differentiation. Thromb Haemost 1997 0.83
135 Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants. Thromb Haemost 1979 0.83
136 Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol 2000 0.83
137 Intron-exon organization of the human gene coding for the lipoprotein-associated coagulation inhibitor: the factor Xa dependent inhibitor of the extrinsic pathway of coagulation. Biochemistry 1991 0.83
138 A novel quantitative multiplex NASBA method: application to measuring tissue factor and CD14 mRNA levels in human monocytes. Nucleic Acids Res 1999 0.83
139 The -589C>T polymorphism in the interleukin-4 gene (IL-4) is associated with a reduced risk of myocardial infarction in young individuals. J Thromb Haemost 2008 0.83
140 Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorbolester. Blood Coagul Fibrinolysis 1994 0.82
141 Two mutations in the promoter region of the human protein C gene both cause type I protein C deficiency by disruption of two HNF-3 binding sites. J Biol Chem 1995 0.82
142 Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb Haemost 1998 0.82
143 Superior sagittal sinus thrombosis in a patient heterozygous for the novel 20210 A allele of the prothrombin gene. Thromb Haemost 1998 0.82
144 Treatment of hereditary protein C deficiency with stanozolol. Thromb Haemost 1987 0.82
145 Three novel mutations in five unrelated subjects with hereditary protein S deficiency type I. J Clin Invest 1994 0.82
146 [Venous thromboses associated with a constitutional deficiency of protein C. 3 cases]. Presse Med 1983 0.82
147 Construction and characterization of thrombin-resistant variants of recombinant human protein S. Thromb Haemost 1994 0.82
148 Two ELISA's for measurement of protein S, and their use in the laboratory diagnosis of protein S deficiency. Clin Chim Acta 1990 0.82
149 Increased tissue factor-initiated prothrombin activation as a result of the Arg506 --> Gln mutation in factor VLEIDEN. J Biol Chem 1997 0.81
150 Inhibitor-neutralisation assay and electro-immuno assay of human factor IX (Christmas factor). Clin Chim Acta 1977 0.81
151 A monoclonal antibody to VIII:C produced by a mouse hybridoma. Blood 1981 0.81
152 Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemost 1987 0.81
153 Role of phagocytosis in activation of the coagulation system in Streptococcus sanguis endocarditis. Infect Immun 1996 0.81
154 A CCA/CCG neutral dimorphism in the codon for Pro 626 of the human protein S gene PS alpha (PROS1). Nucleic Acids Res 1991 0.81
155 Selectin haplotypes and the risk of venous thrombosis: influence of linkage disequilibrium with the factor V Leiden mutation. J Thromb Haemost 2007 0.81
156 Protein C values in coronary artery disease. Br Med J (Clin Res Ed) 1984 0.81
157 Protein C and fibrinolysis: a link between coagulation and fibrinolysis. Adv Exp Med Biol 1990 0.81
158 Unique distance- and DNA-turn-dependent interactions in the human protein C gene promoter confer submaximal transcriptional activity. Biochem J 1999 0.81
159 The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000 0.80
160 Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor--no evidence for a cofactor role of protein S. Thromb Haemost 1988 0.80
161 Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene. Br J Haematol 1998 0.80
162 The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost 1999 0.80
163 Hereditary protein S deficiency in young adults with arterial occlusive disease. Thromb Haemost 1990 0.80
164 Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay. Blood 1996 0.80
165 The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro. Blood 1986 0.80
166 Coagulation factors in the premature infant born after about 32 weeks of gestation. Biol Neonate 1985 0.80
167 Localization of transcription initiation sites in the human coagulation factor IX gene. FEBS Lett 1990 0.80
168 A second plasma inhibitor of activated protein C: alpha 1-antitrypsin. Thromb Haemost 1989 0.80
169 Biochemical prototype for familial thrombosis. A study combining a functional protein C mutation and factor V Leiden. Arterioscler Thromb Vasc Biol 1995 0.79
170 A plasma coagulation assay for an activated protein C-independent anticoagulant activity of protein S. Thromb Haemost 1998 0.79
171 Functional variation in the arginine vasopressin 2 receptor as a modifier of human plasma von Willebrand factor levels. J Thromb Haemost 2010 0.79
172 Involvement of amino acid residues 423-429 of human protein S in binding to C4b-binding protein. Blood Cells Mol Dis 1998 0.79
173 Homozygous protein C deficiency with late onset and recurrent coumarin-induced skin necrosis. Lancet 1992 0.79
174 Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost 1990 0.79
175 Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood 1988 0.79
176 Factor IX Zutphen. A genetic variant of blood coagulation factor IX with an abnormally high molecular weight. J Lab Clin Med 1982 0.79
177 Mutations which introduce free cysteine residues in the Gla-domain of vitamin K dependent proteins result in the formation of complexes with alpha 1-microglobulin. Thromb Haemost 1996 0.79
178 The HR2 haplotype of factor V is not associated with the risk of myocardial infarction. Thromb Haemost 2000 0.79
179 Twelve novel and two recurrent mutations in 14 Austrian families with hereditary protein C deficiency. Blood Coagul Fibrinolysis 1993 0.79
180 Expression and characterization of recombinant human protein S in heterologous cells--studies of the interaction of amino acid residues leu-608 to glu-612 with human C4b-binding protein. Thromb Haemost 1992 0.79
181 Multi-center calibration of the second reference material for thromboplastin rabbit, plain, coded CRM 149R. Thromb Haemost 1991 0.79
182 Studies of the interaction between human protein S and human C4b-binding protein using deletion variants of recombinant human protein S. Thromb Haemost 1994 0.78
183 Location on the human genetic linkage map of 26 genes involved in blood coagulation. Thromb Haemost 1997 0.78
184 Rabbit polyclonal antibodies against the calcium-dependent conformation of factor IX and their application in solid phase immunoradiometric assays. Thromb Haemost 1986 0.78
185 Multi-center study of thromboplastin calibration precision--influence of reagent species, composition, and International Sensitivity Index (ISI). Thromb Haemost 1993 0.78
186 Haemophilia B Leyden: the effect of mutations at position +13 on the liver-specific transcription of the factor IX gene. Blood Coagul Fibrinolysis 1994 0.78
187 Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemost 1984 0.78
188 Functional analysis of two haplotypes of the human endothelial protein C receptor gene. Arterioscler Thromb Vasc Biol 2014 0.78
189 Functional analysis of two polymorphisms in the 3'-UTR of the human prothrombin gene. J Thromb Haemost 2005 0.78
190 The endothelial protein C receptor (EPCR) 23 bp insert mutation and the risk of venous thrombosis. Thromb Haemost 2002 0.78
191 The role of factor IX in tissue thromboplastin induced coagulation. Thromb Haemost 1982 0.78
192 Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 2000 0.78
193 Different sensitivities of various thromboplastins to two blood collection systems for monitoring oral anticoagulant therapy. Thromb Haemost 1999 0.78
194 Identification of eight point mutations in protein S deficiency type I--analysis of 15 pedigrees. Thromb Haemost 1995 0.78
195 Preeclampsia and its interaction with common variants in thrombophilia genes. J Thromb Haemost 2004 0.78
196 Cholesterol or triglyceride loading of human monocyte-derived macrophages by incubation with modified lipoproteins does not induce tissue factor expression. Arterioscler Thromb Vasc Biol 1999 0.78
197 Rapid detection of the prothrombin 20210 A variation by allele specific PCR. Thromb Haemost 1997 0.78
198 Effect of DDAVP on plasma levels of factor VII and XII. Br J Haematol 1984 0.78
199 Factor VII activity and antigen in haemophilia B variants. Thromb Haemost 1980 0.77
200 The human protein S locus: identification of the PS alpha gene as a site of liver protein S messenger RNA synthesis. Biochem Biophys Res Commun 1988 0.77
201 Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia. Br J Haematol 2000 0.77
202 Initiation of Protein S mRNA synthesis in human liver and various cell lines. J Thromb Haemost 2005 0.77
203 Factor IX Zutphen: a Cys18-->Arg mutation results in formation of a heterodimer with alpha 1-microglobulin and the inability to form a calcium-induced conformation. Biochem J 1995 0.77
204 Determination of the allelic and haplotype frequencies of three polymorphisms in the promoter region of the human protein C gene. Blood Coagul Fibrinolysis 1994 0.77
205 Hereditary prothrombin deficiency presenting as intracranial haematoma in infancy. Neuropediatrics 1999 0.77
206 A genetic variant of factor IX with decreased capacity for Ca2+ binding. Br J Haematol 1979 0.77
207 Microparticles expressing tissue factor are concurrently released with markers of inflammation and coagulation during human endotoxemia. J Thromb Haemost 2012 0.77
208 Genome-wide linkage scan in affected sibling pairs identifies novel susceptibility region for venous thromboembolism: Genetics In Familial Thrombosis study. J Thromb Haemost 2013 0.77
209 Preparation of a human factor VII deficient plasma. Thromb Res 1978 0.77
210 Heterogeneity of haemophilia A: a study with three different antisera. Br J Haematol 1982 0.77
211 The use of desmopressin acetate (DDAVP) as a test of the fibrinolytic capacity of patients--analysis of responders and non-responders. Thromb Haemost 1982 0.77
212 Thrombomodulin activity in commercial thromboplastin preparations. Thromb Res 1986 0.77
213 Proteolysis of blood coagulation factor X by activated factor X: difference between the bovine and human proteins. FEBS Lett 1982 0.77
214 Immunoradiometric assays for human coagulation factor VII using polyclonal antibodies against the Ca(II)-dependent and Ca(II)-independent conformation. Thromb Haemost 1986 0.77
215 Factor IXa protects activated factor VIII against inactivation by activated protein C. Biochem Biophys Res Commun 1984 0.77
216 Characterization of a large chromosomal deletion in the PROS1 gene of a patient with protein S deficiency type I using long PCR. Br J Haematol 1996 0.76
217 Effect of synthetic phospholipids on the response of the activated partial thromboplastin time to heparin. Blood Coagul Fibrinolysis 1993 0.76
218 Comparison of functional assays for protein S: European collaborative study of patients with congenital and acquired deficiency. Thromb Haemost 1993 0.76
219 Antigen and functional expression of tissue factor in endotoxin stimulated U937 cells: regulation of activity by calcium ionophore A23187. Thromb Haemost 1995 0.76
220 Hormonal state rather than age influences cut-off values of protein S: reevaluation of the thrombotic risk associated with protein S deficiency. Thromb Haemost 1999 0.76
221 Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med 1987 0.76
222 Two novel and one recurrent missense mutation in the factor XIII A gene in two Dutch patients with factor XIII deficiency. Br J Haematol 2001 0.76
223 Application of factor VII-Sepharose affinity chromatography in the purification of human tissue factor apoprotein. Thromb Res 1986 0.76
224 Activated protein C accelerates clot lysis by virtue of its anticoagulant activity. Blood Coagul Fibrinolysis 1993 0.76
225 Protein C activation by an activator purified from the venom of Agkistrodon halys halys. Blood Coagul Fibrinolysis 1993 0.76
226 Alternative splicing is responsible for the presence of two tissue factor mRNA species in LPS stimulated human monocytes. Thromb Haemost 1992 0.76
227 Prothrombin time ratio is reduced by magnesium contamination in evacuated blood collection tubes. Thromb Haemost 2001 0.76
228 Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004 0.76
229 Activation of the protein C system during cardiopulmonary bypass with and without aprotinin. Ann Thorac Surg 1998 0.75
230 Modification of the N-terminus of human factor IX by defective propeptide cleavage or acetylation results in a destabilized calcium-induced conformation: effects on phospholipid binding and activation by factor XIa. Biochem J 1997 0.75
231 MspI RFLP in intron 8 of the human protein C gene. Nucleic Acids Res 1989 0.75
232 Prothrombin 20210A variant and age at thrombosis. Thromb Haemost 1998 0.75
233 The factor V Leiden mutation (R506Q) is not a major risk factor for migrainous cerebral infarction. Cephalalgia 1997 0.75
234 Compound heterozygosity for one novel and one recurrent mutation in a Thai patient with severe protein S deficiency. Thromb Haemost 1999 0.75
235 The transition G to A at position 20210 in the 3'-untranslated region of the prothrombin gene is not associated with migrainous infarction. Cephalalgia 1998 0.75
236 Two RFLPS approximately 7 kb 5' of the human protein C gene. Nucleic Acids Res 1988 0.75
237 The effects of phosphate and electron transport on the carbonyl cyanide m-chlorophenylhydrazone-induced ATPase of rat-liver mitochondria. Biochim Biophys Acta 1975 0.75
238 A mutation in the protein S pseudogene is linked to protein S deficiency in a thrombophilic family. Thromb Haemost 1989 0.75
239 Immunoradiometric assay of procoagulant factor VIII antigen (VIIICAG). Clin Chim Acta 1980 0.75
240 Immunoradiometric assay for the calcium-stabilized conformation of human protein S. Thromb Haemost 1987 0.75
241 Compound heterozygosity for two novel missense mutations in the prothrombin gene in a patient with a severe bleeding tendency. Thromb Haemost 1997 0.75
242 The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model. Blood Coagul Fibrinolysis 2002 0.75
243 Haplotypes of the fibrinogen gamma gene do not affect the risk of myocardial infarction. J Thromb Haemost 2006 0.75
244 Molecular basis of hereditary protein C and protein S deficiency. Curr Stud Hematol Blood Transfus 1991 0.75
245 The effect of factor V Leiden, oral contraceptive use, type of oral contraceptives and pregnancy on APC-r levels in women with or without a history of pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2001 0.75
246 Protein C antigen levels in major abdominal surgery: relationships to deep vein thrombosis, malignancy and treatment with stanozolol. Thromb Haemost 1985 0.75
247 Extrinsic activation of human blood coagulation factors IX and X. Thromb Haemost 1990 0.75
248 Effect of stanozolol on antithrombin III and protein C. Lancet 1983 0.75
249 Immunologic studies on the relationship between FVIII related antigen and FVIII procoagulant activity. Thromb Res 1980 0.75
250 Inherited prethrombotic disorders and infectious purpura. Thromb Haemost 1996 0.75
251 Carrier detection of haemophilia B by using an intragenic restriction-fragment length polymorphism. Thromb Haemost 1985 0.75
252 Severe deep vein thrombosis in a 2-year-old child with protein S deficiency. Thromb Haemost 1987 0.75
253 Identification of residues in the Gla-domain of human factor IX involved in the binding to conformation specific antibodies. Biochim Biophys Acta 1998 0.75
254 Critical appraisal, clinical usefulness, and implementation of the thromboplastin concept of prothrombin-time standardization. Scand J Haematol Suppl 1980 0.75
255 [Search for the carrier state of hemophilia B using restriction fragment length polymorphism]. Ned Tijdschr Geneeskd 1985 0.75
256 [New risk factors in the development of venous thrombosis]. Ned Tijdschr Geneeskd 1985 0.75
257 Application of two neutral MspI DNA polymorphisms in the analysis of hereditary protein C deficiency. Thromb Haemost 1990 0.75
258 Identification of evolutionarily invariant sequences in the protein C gene promoter. J Mol Evol 1998 0.75
259 Two novel mutations in the prothrombin gene cause severe bleeding in a compound heterozygous patient. Blood Coagul Fibrinolysis 1998 0.75
260 Partial reconstitution of factor VIII activity from a mild Crm+ hemophilia A patient by replacement of the defective A2 domain. Thromb Haemost 1998 0.75
261 Protein C, an anticoagulant protein, is increased in healthy volunteers and surgical patients after treatment with stanozolol. Thromb Res 1984 0.75
262 A new functional assay of thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2005 0.75
263 The fibrinolytic system in patients with congenital protein C deficiency. Thromb Res 1984 0.75
264 An international collaborative study on the performance of protein C antigen assays. Report of the ICTH subcommittee on protein C. International Committee on Thrombosis and Haemostasis. Thromb Haemost 1987 0.75
265 Immunoradiometric assays for the Ca(II)-dependent and Ca(II)-independent conformation of human protein C. Thromb Res 1988 0.75
266 The functional defect of factor VIII Leiden, a genetic variant of coagulation factor VIII. Thromb Haemost 1985 0.75
267 High factor VIII levels contribute to the thrombotic risk in families with factor V Leiden. Br J Haematol 2001 0.75
268 Careful selection of sample dilution and factor-V-deficient plasma makes the modified activated protein C resistance test highly specific for the factor V Leiden mutation. Blood Coagul Fibrinolysis 1999 0.75
269 Haemostatic effects of stanozolol in elderly medical patients. Thromb Res 1984 0.75
270 [The causes of venous thrombosis and lung embolism]. Ned Tijdschr Geneeskd 1985 0.75
271 Use of coagulation assays in prenatal diagnosis of haemophilia A and B. Lancet 1981 0.75
272 [A family with venous thrombosis and hereditary protein S deficiency]. Ned Tijdschr Geneeskd 1987 0.75
273 [Protein C deficiency--a risk factor for venous thrombosis]. Klin Wochenschr 1984 0.75
274 Prothrombotic mutations and ischaemic stroke at a young age in two sisters. J Neurol Neurosurg Psychiatry 1998 0.75
275 A PstI RFLP of the LACI gene. Nucleic Acids Res 1990 0.75
276 Characterization of an immunologic polymorphism (D79H) in the heavy chain of factor V. J Thromb Haemost 2004 0.75
277 [High concentration of coagulation factor VIII as a risk factor for thrombosis]. Ned Tijdschr Geneeskd 2001 0.75
278 Multicenter evaluation of three commercial methods for measuring protein S antigen. Thromb Haemost 1992 0.75
279 Alterations in the extrinsic pathway in hypertriglyceridemia do not cause a 'procoagulant state': effects of bezafibrate therapy. Blood Coagul Fibrinolysis 2001 0.75
280 The usefulness of single-strand DNA conformation polymorphism analysis to detect mutations in protein C deficiency. Blood Coagul Fibrinolysis 1997 0.75
281 New method for the rapid detection of vitamin k deficiency. Clin Chim Acta 1980 0.75
282 Affinities of ATP for the dinitrophenol-induced ATPase. Biochim Biophys Acta 1973 0.75
283 Tissue factor-induced coagulation can be inhibited by aprotinin (Trasylol) Thromb Haemost 1993 0.75
284 Protein concentrates for therapeutic use. Lancet 1982 0.75
285 Solid phase immunoradiometric assay of activated human coagulation factor IX. Thromb Res 1987 0.75
286 Separating short tandem repeat polymorphisms on microgel. Anal Biochem 1997 0.75